|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart BW and Wild CP: Colorectal
cancerWorld Cancer Report 2014. IARC Publications; pp. 392–402.
2014
|
|
4
|
Laiyemo AO, Doubeni C, Pinsky PF, Doria
Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M,
Hickey T, et al: Race and colorectal cancer disparities:
Health-care utilization vs different cancer susceptibilities. J
Natl Cancer Inst. 102:538–546. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Hees F, Saini SD, Lansdorp-Vogelaar I,
Vijan S, Meester RG, de Koning HJ, Zauber AG and van Ballegooijen
M: Personalizing colonoscopy screening for elderly individuals
based on screening history, cancer risk, and comorbidity status
could increase cost effectiveness. Gastroenterology. 149:1425–1437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma W, Yu Q, Jiang J, Du X, Huang L, Zhao L
and Zhou QI: miR-517a is an independent prognostic marker and
contributes to cell migration and invasion in human colorectal
cancer. Oncol Lett. 11:2583–2589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tonini T, D'Andrilli G, Fucito A, Gaspa L
and Bagella L: Importance of Ezh2 polycomb protein in tumorigenesis
process interfering with the pathway of growth suppressive key
elements. J Cell Physiol. 214:295–300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Margueron R and Reinberg D: The Polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan
J, Selvarajan V, Liu SC, Bi C, Wang S, et al: EZH2 overexpression
in natural killer/T-cell lymphoma confers growth advantage
independently of histone methyltransferase activity. Blood.
121:4512–4520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sneeringer CJ, Scott MP, Kuntz KW, Knutson
SK, Pollock RM, Richon VM and Copeland RA: Coordinated activities
of wild-type plus mutant EZH2 drive tumor-associated
hypertrimethylation of lysine 27 on histone H3 (H3K27) in human
B-cell lymphomas. Proc Natl Acad Sci USA. 107:pp. 20980–20985.
2010; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orkin SH and Hochedlinger K: Chromatin
connections to pluripotency and cellular reprogramming. Cell.
145:835–850. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bracken AP, Pasini D, Capra M, Prosperini
E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway,
essential for proliferation and amplified in cancer. EMBO J.
22:5323–5335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herrera-Merchan A, Arranz L, Ligos JM, de
Molina A, Dominguez O and Gonzalez S: Ectopic expression of the
histone methyltransferase Ezh2 in haematopoietic stem cells causes
myeloproliferative disease. Nat Commun. 3:6232012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:pp. 11606–11611. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sudo T, Utsunomiya T, Mimori K, Nagahara
H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K and Mori M:
Clinicopathological significance of EZH2 mRNA expression in
patients with hepatocellular carcinoma. Br J Cancer. 92:1754–1758.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bachmann IM, Halvorsen OJ, Collett K,
Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP and
Akslen LA: EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma and
cancers of the endometrium, prostate, and breast. J Clin Oncol.
24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weikert S, Christoph F, Köllermann J,
Müller M, Schrader M, Miller K and Krause H: Expression levels of
the EZH2 polycomb transcriptional repressor correlate with
aggressiveness and invasive potential of bladder carcinomas. Int J
Mol Med. 16:349–353. 2005.PubMed/NCBI
|
|
19
|
Zingg D, Debbache J, Schaefer SM, Tuncer
E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y and
Bonalli M: The epigenetic modifier EZH2 controls melanoma growth
and metastasis through silencing of distinct tumor suppressors. Nat
Commun. 6:60512015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang CJ, Yang JY, Xia W, Chen CT, Xie X,
Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Landen CN Jr, Chavez-Reyes A, Bucana C,
Schmandt R, Deavers MT, Lopez-Berestein G and Sood AK: Therapeutic
EphA2 gene targeting in vivo using neutral liposomal small
interfering RNA delivery. Cancer Res. 65:6910–6918. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang W, Bikard D, Cox D, Zhang F and
Marraffini LA: RNA-guided editing of bacterial genomes using
CRISPR-Cas systems. Nat Biotechnol. 31:233–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wittekind C, Compton CC, Greene FL and
Sobin LH: TNM residual tumor classification revisited. Cancer.
94:2511–2516. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuang Y, Lu F, Guo J, Xu H, Wang Q, Xu C,
Zeng L and Yi S: Histone demethylase KDM2B upregulates histone
methyltransferase EZH2 expression and contributes to the
progression of ovarian cancer in vitro and in vivo. Onco Targets
Ther. 10:3131–3144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kirk JS, Sachaarchuch K, Dalimov Z,
Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili
R and Ellis L: Top2a identifies and provides epigenetic rationale
for novel combination therapeutic strategies for aggressive
prostate cancer. Oncotarget. 6:3136–3146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fillmore CM, Xu C, Desai PT, Berry JM,
Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK
and Kim CF: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung
tumours to TopoII inhibitors. Nature. 520:239–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McCabe MT, Ott HM, Ganji G, Korenchuk S,
Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III,
Diaz E, et al: EZH2 inhibition as a therapeutic strategy for
lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qi W, Chan H, Teng L, Li L, Chuai S, Zhang
R, Zeng J, Li M, Fan H, Lin Y, et al: Selective inhibition of Ezh2
by a small molecule inhibitor blocks tumor cells proliferation.
Proc Natl Acad Sci USA. 109:pp. 21360–21365. 2012; View Article : Google Scholar : PubMed/NCBI
|
